证券代码：601133 证券简称：柏诚股份 公告编号：2025-072 柏诚系统科技股份有限公司 关于已中标重大项目签订合同的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、基本情况概述 公司于2025年9月30日披露了《关于公司重大项目中标的公告》（公告编号： 1 交易概述：柏诚系统科技股份有限公司（以下简称"公司"）与某客户 签署某洁净相关项目工程合同（以下简称"合同"）。 合同类型及总金额 合同类型：日常经营合同 合同总金额：3.25亿元（含税）。 本次交易不构成关联交易，不构成重大资产重组。 对上市公司业绩的影响：合同的签订有助于公司业务的发展，合同收入 根据履约进度逐步确认，合同履行会对公司收入产生积极影响。该合同 的履行对公司业务独立性不构成影响，亦不会因履行该合同而对合同交 易对手方形成依赖。 特别风险提示：合同各方均具有履约能力，但在合同履约过程中，如遇 政策、市场、环境等不可预计或不可抗力等因素影响，可能会导致合同 无法如期或全面履行，合同履行存在一定的不确定性。敬请广大投资者 ...

证券代码：601133 证券简称：柏诚股份 公告编号：2025-070 对于存在客观证据表明存在减值，以及其他适用于单项评估的应收票据、应 收账款，其他应收款、应收款项融资、合同资产及长期应收款等单独进行减值测 试，确认预期信用损失，计提单项减值准备。对于不存在减值客观证据的应收票 1 柏诚系统科技股份有限公司 关于 2025 年 1-9 月计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 柏诚系统科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开 第七届董事会第十七次会议，审议通过了《关于 2025 年 1-9 月计提资产减值准 备的议案》，现将相关情况公告如下： 一、计提资产减值准备情况 2025 年 1-9 月，公司根据《企业会计准则》及公司会计政策的相关规定，本 着谨慎性原则，对应收款项、合同资产（包含重分类列示于其他非流动资产的到 期期限在一年以上的质保金）计提信用减值损失及资产减值损失，具体情况如下： 注：上述表格数据如有尾差，系四舍五入造成。 二、计提资产减值准备的 ...

证券代码：601133 证券简称：柏诚股份 公告编号：2025-071 柏诚系统科技股份有限公司 第七届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 柏诚系统科技股份有限公司（以下简称"公司"）第七届董事会第十七次会 议于 2025 年 10 月 28 日以现场结合通讯的方式在公司会议室召开。会议通知已 于 2025 年 10 月 25 日通过邮件的方式送达全体董事。本次会议由董事长过建廷 主持，会议应出席董事 8 人，实际出席董事 8 人。公司全体高级管理人员列席本 次会议。本次会议的召集、召开符合《公司法》《公司章程》的有关规定，决议 内容合法有效。 二、董事会会议审议情况 （一）审议通过《关于<2025 年第三季度报告>的议案》 董事会认为： 1、公司 2025 年第三季度报告的编制和审核程序符合法律、法规及《公司章 程》等相关规定，公司 2025 年第三季度报告包含的信息公允、全面、真实地反 映了公司本报告期的财务状况和经营成果等事项。 2、董事会保证公司 2025 ...

柏诚系统科技股份有限公司 2025 年第三季度报告 证券代码：601133 证券简称：柏诚股份 柏诚系统科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 注："本报告期"指本季度初至本季度末 3 个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 | 非经常性损益项目 | 本期金额 | 年初至报告 期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益，包括已计提资产减值准备的冲销 | -220.75 | -45,280.52 | | ...

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year [1] Financial Performance - Third quarter revenue was 853 million yuan, a year-on-year decrease of 36.16% [1] - Third quarter net profit was 49.46 million yuan, a year-on-year decrease of 16.41% [1] - Revenue for the first three quarters was 3.276 billion yuan, a year-on-year decrease of 14.63% [1] - Net profit for the first three quarters was 133 million yuan, a year-on-year decrease of 16.22% [1]

Core Viewpoint - The company, 柏诚股份 (601133.SH), has clarified that it currently has no business cooperation relationship with 新凯 [1] Group 1 - 柏诚股份 confirmed the absence of any business collaboration with 新凯来 [1]

Core Viewpoint - The acquisition plan by Baicheng Co., Ltd. (601133) to purchase 55% of Shanghai Canxi Engineering Equipment Co., Ltd. has been terminated due to failure to reach agreement on key terms, leading to the end of the deal just 10 days after its announcement [1][5]. Group 1: Acquisition Details - Baicheng Co. announced the termination of the acquisition plan on October 10, 2023, which had been under consideration since September 30, 2023 [1]. - The company had previously signed an investment cooperation framework agreement with the sellers, which included specific pricing based on a report from a qualified assessment agency [5]. - The termination of the acquisition is stated not to adversely affect the company's business operations, financial status, or shareholder interests [5][6]. Group 2: Financial Performance - Baicheng Co. has experienced a decline in net profit, with a year-on-year decrease of 14.7% in 2023, followed by a further decline of 0.8% in 2024, and a continuation of this trend in the first half of 2025 [6][8]. - The company's revenue for the first half of 2025 was reported at 2.424 billion yuan, a decrease of 3.14% year-on-year, with a net profit attributable to shareholders of 83.4953 million yuan, reflecting a decline of 16.1% [8]. - The primary reason for the profit decline is attributed to an increase in bad debt provisions for contract assets, with asset impairment losses reaching 50.8 million yuan, a significant increase of 55% compared to the same period last year [8].

Core Viewpoint - 柏诚股份 has terminated its plan to acquire 55% of Shanghai Canxi Engineering Equipment Co., Ltd. through a combination of issuing shares and cash payment, leading to the resumption of its stock trading on October 13, 2025 after a suspension since September 30, 2025 [1][2] Group 1: Transaction Details - The company had initially planned to purchase shares from several parties, including Zhou Huajie and others, and to raise additional funds through a share issuance [1] - The termination of the transaction was due to the inability to reach an agreement on key terms between the parties involved, despite ongoing discussions during the suspension period [2] - The company stated that the termination would not adversely affect its business operations or financial status, nor harm the interests of its shareholders, particularly minority shareholders [2] Group 2: Financial Performance - In 2024, 柏诚股份 reported a revenue of 5.24 billion yuan, representing a year-on-year increase of 31.78%, while the net profit attributable to shareholders was 212.26 million yuan, a slight decrease of 0.80% [3][4] - The net profit after excluding non-recurring gains and losses was 204.39 million yuan, down 2.49% from the previous year [4] - For the first half of 2025, the company experienced a revenue decline of 3.14% to 2.42 billion yuan, with a net profit of 83 million yuan, reflecting a 16.10% decrease [5]

Core Viewpoint - The company has terminated the planned acquisition of 55% of Shanghai CanShine Engineering Equipment Co., Ltd., which has drawn market attention, but this decision will not adversely affect its business operations or financial status [1][2]. Group 1: Acquisition Details - The acquisition was aimed at addressing core pain points in the biopharmaceutical sector and enhancing the company's strategic layout in this area [2]. - Shanghai CanShine possesses core capabilities in high-end biopharmaceuticals, including monoclonal antibodies and vaccines, which align well with the company's existing business [2]. - The termination of the acquisition was due to the inability to reach consensus on key terms, reflecting the company's commitment to shareholder interests and prudent decision-making [2][3]. Group 2: Strategic Focus - The company remains committed to its strategic focus in the semiconductor and biopharmaceutical sectors, emphasizing its modular overall solutions that meet overseas biopharmaceutical clients' needs for efficient delivery and compliance [3]. - Continuous investment in independent innovation has led to the establishment of a modular manufacturing base, supporting scalable and standardized development [3]. - The company plans to leverage favorable policies and market conditions to enhance its integrated solutions in biopharmaceutical cleanroom systems and core process systems, aiming to meet evolving customer demands and improve competitive strength [3].

Core Viewpoint - The acquisition plan by Baicheng Co., Ltd. to purchase 55% of Shanghai Canxi Engineering Equipment Co., Ltd. has been terminated due to the inability to reach an agreement on key terms of the transaction within a short period of 10 days [1][3]. Group 1: Acquisition Details - Baicheng Co. announced the termination of the acquisition plan on October 10, following a suspension of trading that began on September 30 [1]. - The company had previously signed an investment cooperation framework agreement with several parties, including Zhou Huajie and Tai Qing, to facilitate the acquisition [3]. - The transaction was not expected to constitute a major asset restructuring or related party transaction, nor would it lead to a change in the actual controller of the company [3]. Group 2: Financial Performance - Baicheng Co. has experienced a continuous decline in financial performance, with a 14.7% decrease in net profit in 2023 and a further 0.8% decline projected for 2024 [4]. - The company's revenue for the first half of 2025 was reported at 2.424 billion yuan, a year-on-year decrease of 3.14%, while the net profit attributable to shareholders fell by 16.1% to 83.4953 million yuan [6]. - The decline in profit is attributed to an increase in the provision for bad debts related to contract assets, with asset impairment losses reaching 50.8 million yuan, a 55% increase compared to the same period last year [6].